Sign Up Today and Learn More About Artios Pharma Stock
Invest in or calculate the value of your shares in Artios Pharma or other pre-IPO companies through EquityZen's platform.
Artios Pharma Stock
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
About Artios Pharma Stock
Founded
2016
Industries
Travel and Tourism, Manufacturing, Space
Artios Pharma Press Mentions
Stay in the know about the latest news on Artios Pharma
DNA Damaging Agents Market Grows at 11.67% CAGR, to Hit USD 46.31 Billion by 2034
globenewswire • Nov 27, 2025
ADC specialist Solve raises $120m, and other biofinancings
pharmaphorum • Nov 23, 2025
US investors heavily back Artios Pharma $115m Series D growth round
businessweekly • Nov 19, 2025
Artios raises £87m Series D funding to target cancers via DNA
businesscloud • Nov 19, 2025
Companies House identity verification changes come into force
businesscloud • Nov 19, 2025
Artios Pharma Management
Leadership team at Artios Pharma
COO & Founder
Andrew Muncey
Director & CEO
Michael Andriole
Join now and verify your accreditation status to gain access to:
- Artios Pharma Current Valuation
- Artios Pharma Stock Price
- Artios Pharma Management
- Available deals in Artios Pharma and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Artios Pharma Cap Table and Funding History by Share Class and Liquidity Preferences
- Artios Pharma Revenue and Financials
- Artios Pharma Highlights
- Artios Pharma Business Model
- Artios Pharma Risk Factors
- Artios Pharma Research Report from SACRA Research
Trading Artios Pharma Stock
How to invest in Artios Pharma stock?
Accredited investors can buy pre-IPO stock in companies like Artios Pharma through EquityZen funds. These investments are made available by existing Artios Pharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Artios Pharma stock?
Shareholders can sell their Artios Pharma stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."